Products

Iso-14888-3-revision-checker

The signature amendment is approved. EdDSA is in.

iso-14888-3-revision-checker.pages.dev Legal & Compliance / Compliance Automation

Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$49/mo
Lower than 49% of peersNiche median $49/mo
Creators
Unlinked
No verified creators
Launched
29d ago
2026-10-23 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    EdDSA amendment

    Oct 23 · 29d agoLaunch page

    At the time: <5K visits/mo

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2020-09-02

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

The kit
$799/once
The watch
$49/mo

Trial: None · 2 paid tiers ($49–$799) · Observed 2026-11-07 · Pricing page

Entry price $49/mo, Lower than 49% of peers; “Compliance Automation” median is $49/mo.View pricing benchmark

Website snapshots

Indexed 2026-10-23

Key pages

Desktop & mobile archive

Questions & evidence

How much does Iso-14888-3-revision-checker cost?
The kit: $799/once; The watch: $49/mo. Observed 2026-11-07. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does Iso-14888-3-revision-checker get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Iso-14888-3-revision-checker and what platforms does it support?
Iso-14888-3-revision-checker is catalogued under Compliance Automation: The signature amendment is approved. EdDSA is in. Supported platforms: Web.

Related products in this category

Legal & Compliance / Compliance Automation

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.